Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
Article
Google Scholar
Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, et al. Prostate cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17:479–505.
CAS
Article
Google Scholar
Mason BR, Eastham JA, Davis BJ, Mynderse LA, Pugh TJ, Lee RJ, et al. Current status of MRI and PET in the NCCN guidelines for prostate cancer. J Natl Compr Canc Netw. 2019;17:506–13.
CAS
Article
Google Scholar
Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208–16.
CAS
Article
Google Scholar
Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic efficacy of 68 gallium-PSMA positron emission tomography compared to conventional imaging for lymph node Staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol. 2016;195:1436–43.
Article
Google Scholar
Rauscher I, Maurer T, Beer AJ, Graner F-P, Haller B, Weirich G, et al. Value of 68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy. J Nucl Med. 2016;57:1713–9.
CAS
Article
Google Scholar
Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668–74.
Article
Google Scholar
Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. 68Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44:1014–24.
Article
Google Scholar
Sheikhbahaei S, Afshar-Oromieh A, Eiber M, Solnes LB, Javadi MS, Ross AE, et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging. 2017;44:2117–36.
Article
Google Scholar
Hofman MS, Hicks RJ, Maurer T, Eiber M. Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiographics. 2018;38:200–17.
Article
Google Scholar
Rauscher I, Krönke M, König M, Gafita A, Maurer T, Horn T, et al. Matched-pair comparison of 68 Ga-PSMA-11 PET/CT and 18 F-PSMA-1007 PET/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy. J Nucl Med. 2020;61:51–7.
CAS
Article
Google Scholar
Eiber M, Nekolla SG, Maurer T, Weirich G, Wester H-J, Schwaiger M. 68Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer. Abdom Imaging. 2015;40:1769–71.
Article
Google Scholar
Giesel FL, Kesch C, Yun M, Cardinale J, Haberkorn U, Kopka K, et al. 18F-PSMA-1007 PET/CT detects micrometastases in a patient with biochemically recurrent prostate cancer. Clin Genitourin Cancer. 2017;15:e497–9.
Article
Google Scholar
Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. J Nucl Med. 2018;59:469–78.
Article
Google Scholar
Rowe SP, Pienta KJ, Pomper MG, Gorin MA. Proposal for a structured reporting system for prostate-specific membrane antigen–targeted PET imaging: PSMA-RADS version 1.0. J Nucl Med. 2018;59:479–85.
Article
Google Scholar
Ceci F, Oprea-Lager DE, Emmett L, Adam JA, Bomanji J, Czernin J, et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05245-y
Grubmüller B, Senn D, Kramer G, Baltzer P, D’Andrea D, Grubmüller KH, et al. Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1063–72.
Article
Google Scholar
Seifert R, Herrmann K, Kleesiek J, Schäfers M, Shah V, Xu Z, et al. Semiautomatically quantified tumor volume using 68 Ga-PSMA-11 PET as a biomarker for survival in patients with advanced prostate cancer. J Nucl Med. 2020;61:1786–92.
CAS
Article
Google Scholar
Schmidkonz C, Cordes M, Schmidt D, Bäuerle T, Goetz TI, Beck M, et al. 68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:1862–72.
Article
Google Scholar
Seifert R, Kessel K, Schlack K, Weber M, Herrmann K, Spanke M, et al. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis. Eur J Nucl Med Mol Imaging. 2021;48:1200–10.
CAS
Article
Google Scholar
Hartenstein A, Lübbe F, Baur ADJ, Rudolph MM, Furth C, Brenner W, et al. Prostate cancer nodal staging: using deep learning to predict 68Ga-PSMA-positivity from CT imaging alone. Sci Rep. 2020;10:3398.
CAS
Article
Google Scholar
Bieth M, Krönke M, Tauber R, Dahlbender M, Retz M, Nekolla SG, et al. Exploring new multimodal quantitative imaging indices for the assessment of osseous tumor burden in prostate cancer using 68 Ga-PSMA PET/CT. J Nucl Med. 2017;58:1632–7.
CAS
Article
Google Scholar
Hammes J, Täger P, Drzezga A. EBONI: a tool for automated quantification of bone metastasis load in PSMA PET/CT. J Nucl Med. 2018;59:1070–5.
CAS
Article
Google Scholar
Gafita A, Bieth M, Krönke M, Tetteh G, Navarro F, Wang H, et al. qPSMA: semiautomatic software for whole-body tumor burden assessment in prostate cancer using 68 Ga-PSMA11 PET/CT. J Nucl Med. 2019;60:1277–83.
CAS
Article
Google Scholar
Zhao Y, Gafita A, Vollnberg B, Tetteh G, Haupt F, Afshar-Oromieh A, et al. Deep neural network for automatic characterization of lesions on 68Ga-PSMA-11 PET/CT. Eur J Nucl Med Mol Imaging. 2020;47:603–13.
CAS
Article
Google Scholar
Sibille L, Seifert R, Avramovic N, Vehren T, Spottiswoode B, Zuehlsdorff S, et al. 18 F-FDG PET/CT uptake classification in lymphoma and lung cancer by using deep convolutional neural networks. Radiology. 2020;294:445–52.
Article
Google Scholar
Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50:122S-150S.
CAS
Article
Google Scholar
Camacho MR, Etchebehere E, Tardelli N, Delamain MT, Vercosa AFA, Takahashi MES, et al. Validation of a multifocal segmentation method for measuring metabolic tumor volume in Hodgkin lymphoma. J Nucl Med Technol. 2020;48:30–5.
Article
Google Scholar
Barrington SF, Meignan M. Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden. J Nucl Med. 2019;60:1096–102.
Article
Google Scholar
Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.
CAS
Article
Google Scholar
Pfaehler E, Mesotten L, Kramer G, Thomeer M, Vanhove K, de Jong J, et al. Repeatability of two semi-automatic artificial intelligence approaches for tumor segmentation in PET. EJNMMI Res. 2021;11:4.
Article
Google Scholar
Hatt M, Laurent B, Ouahabi A, Fayad H, Tan S, Li L, et al. The first MICCAI challenge on PET tumor segmentation. Med Image Anal. 2018;44:177–95.
Article
Google Scholar
Weisman AJ, Kieler MW, Perlman S, Hutchings M, Jeraj R, Kostakoglu L, et al. Comparison of 11 automated PET segmentation methods in lymphoma. Phys Med Biol. 2020;65:235019.
CAS
Article
Google Scholar
Jemaa S, Fredrickson J, Carano RAD, Nielsen T, de Crespigny A, Bengtsson T. Tumor segmentation and feature extraction from whole-body FDG-PET/CT using cascaded 2D and 3D convolutional neural networks. J Digit Imaging. 2020;33:888–94.
Article
Google Scholar
Blanc-Durand P, Jégou S, Kanoun S, Berriolo-Riedinger A, Bodet-Milin C, Kraeber-Bodéré F, et al. Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network. Eur J Nucl Med Mol Imaging. 2021;48:1362–70.
CAS
Article
Google Scholar
Hartrampf PE, Heinrich M, Seitz AK, Brumberg J, Sokolakis I, Kalogirou C, et al. Metabolic tumour volume from PSMA PET/CT scans of prostate cancer patients during chemotherapy—do different software solutions deliver comparable results? J Clin Med. 2020;9:1390.
CAS
Article
Google Scholar